Tandem t:slim X2 Insulin Pump Now Compatible with Dexcom G7 CGM in Canada
Tandem Diabetes Care and Dexcom announced that Health Canada has authorized the sale of the t:slim X2™ insulin pump with full compatibility for both Dexcom G6 and G7 Continuous Glucose Monitoring (CGM) Systems. This makes the t:slim X2 the first insulin pump in Canada integrated with both CGMs. The t:slim X2, which features Control-IQ technology, is highly rated and now offers Canadian users more options for diabetes management.
The integration launched in the U.S. in December 2023, and now Canadian users can benefit from the faster 30-minute sensor warm-up time of the Dexcom G7 and the ability to view glucose levels on an Apple smartwatch. Tandem will provide the new compatibility feature free of charge via a remote software update to in-warranty users and will begin shipping updated pumps in early January 2025. For more information, users can visit tandemdiabetes.ca or dexcom.com.
Tandem Diabetes Care e Dexcom hanno annunciato che Health Canada ha autorizzato la vendita della pompa per insulina t:slim X2™ con piena compatibilità sia per i sistemi di monitoraggio della glicemia continua G6 che G7. Questo rende la t:slim X2 la prima pompa per insulina in Canada integrata con entrambi i CGM. La t:slim X2, che presenta la tecnologia Control-IQ, è molto apprezzata e ora offre agli utenti canadesi più opzioni per la gestione del diabete.
L'integrazione è stata lanciata negli Stati Uniti a dicembre 2023, e ora gli utenti canadesi possono beneficiare del tempo di riscaldamento del sensore di 30 minuti del Dexcom G7 e della possibilità di visualizzare i livelli di glucosio su un orologio Apple. Tandem fornirà la nuova funzione di compatibilità gratuitamente tramite un aggiornamento software remoto agli utenti in garanzia e inizierà a spedire le pompe aggiornate all'inizio di gennaio 2025. Per ulteriori informazioni, gli utenti possono visitare tandemdiabetes.ca o dexcom.com.
Tandem Diabetes Care y Dexcom anunciaron que Health Canada ha autorizado la venta de la bomba de insulina t:slim X2™ con plena compatibilidad para los sistemas de monitoreo continuo de glucosa G6 y G7. Esto convierte a la t:slim X2 en la primera bomba de insulina en Canadá integrada con ambos CGMs. La t:slim X2, que cuenta con la tecnología Control-IQ, tiene alta calificación y ahora ofrece a los usuarios canadienses más opciones para el manejo de la diabetes.
La integración se lanzó en los EE.UU. en diciembre de 2023, y ahora los usuarios canadienses pueden beneficiarse del tiempo de calentamiento del sensor de 30 minutos del Dexcom G7 y de la capacidad de ver los niveles de glucosa en un reloj inteligente de Apple. Tandem proporcionará la nueva función de compatibilidad de forma gratuita a través de una actualización de software remota para los usuarios con garantía y comenzará a enviar las bombas actualizadas a principios de enero de 2025. Para más información, los usuarios pueden visitar tandemdiabetes.ca o dexcom.com.
탄뎀 다이어베틱스 케어(Tandem Diabetes Care)와 덱스콤(Dexcom)은 건강 캐나다(Health Canada)가 t:slim X2™ 인슐린 펌프의 판매를 승인했으며, G6 및 G7 연속 혈당 모니터링(CGM) 시스템과 완벽하게 호환된다고 발표했습니다. 이는 t:slim X2가 두 개의 CGM과 통합된 캐나다 최초의 인슐린 펌프가 되었다는 의미입니다. Control-IQ 기술이 특징인 t:slim X2는 높이 평가받고 있으며, 이제 캐나다 사용자에게 당뇨 관리에 대한 더 많은 옵션을 제공합니다.
이 통합은 2023년 12월 미국에서 출시되었으며, 이제 캐나다 사용자들은 Dexcom G7의 30분 센서 예열 시간과 Apple 스마트워치에서 혈당 수치를 볼 수 있는 기능의 혜택을 누릴 수 있습니다. 탄뎀은 새로운 호환성 기능을 보증 기간이 남아 있는 사용자에게 원격 소프트웨어 업데이트를 통해 무료로 제공하며, 2025년 1월 초부터 업데이트된 펌프를 배송하기 시작할 것입니다. 자세한 정보는 tandemdiabetes.ca 또는 dexcom.com을 방문하십시오.
Tandem Diabetes Care et Dexcom ont annoncé que Santé Canada a autorisé la vente de la pompe à insuline t:slim X2™ avec une compatibilité complète pour les systèmes de surveillance continue de la glucose G6 et G7. Cela fait de la t:slim X2 la première pompe à insuline au Canada intégrée avec les deux CGM. La t:slim X2, qui dispose de la technologie Control-IQ, est très appréciée et offre désormais aux utilisateurs canadiens plus d'options pour la gestion du diabète.
L'intégration a été lancée aux États-Unis en décembre 2023, et maintenant les utilisateurs canadiens peuvent bénéficier du temps de réchauffement de 30 minutes du capteur du Dexcom G7 ainsi que de la possibilité de visualiser les niveaux de glucose sur une montre connectée Apple. Tandem fournira la nouvelle fonction de compatibilité gratuitement via une mise à jour logicielle à distance aux utilisateurs sous garantie et commencera à expédier les pompes mises à jour début janvier 2025. Pour plus d'informations, les utilisateurs peuvent visiter tandemdiabetes.ca ou dexcom.com.
Tandem Diabetes Care und Dexcom haben bekannt gegeben, dass Health Canada den Verkauf der t:slim X2™ Insulinpumpe mit kompletter Kompatibilität für sowohl die Dexcom G6 als auch G7 kontinuierlichen Glukoseüberwachungssysteme genehmigt hat. Damit ist die t:slim X2 die erste Insulinpumpe in Kanada, die mit beiden CGMs integriert ist. Die t:slim X2, die über Control-IQ-Technologie verfügt, hat hohe Bewertungen erhalten und bietet den kanadischen Nutzern nun mehr Optionen für das Diabetesmanagement.
Die Integration wurde im Dezember 2023 in den USA eingeführt, und jetzt können kanadische Nutzer von der schnelleren Sensor-Aufwärmzeit von 30 Minuten des Dexcom G7 sowie der Möglichkeit profitieren, den Glukosespiegel auf einer Apple-Smartwatch anzuzeigen. Tandem wird das neue Kompatibilitätsfeature kostenlos über ein Fernsoftware-Update an Benutzer mit Garantie bereitstellen und beginnt Anfang Januar 2025 mit dem Versand der aktualisierten Pumpen. Weitere Informationen erhalten Sie unter tandemdiabetes.ca oder dexcom.com.
- Health Canada authorized the sale of t:slim X2 with Dexcom G7 compatibility.
- t:slim X2 is the first insulin pump in Canada integrated with both Dexcom G6 and G7.
- Users benefit from the faster 30-minute sensor warm-up time of Dexcom G7.
- Free remote software update for in-warranty users.
- None.
Insights
The integration of Dexcom G7 with Tandem's t:slim X2 insulin pump in Canada represents a significant technological advancement in diabetes care. The system's 30-minute sensor warm-up time and compatibility with both G6 and G7 CGM systems provide enhanced flexibility and convenience for patients. This dual compatibility, combined with the Apple Watch integration, positions Tandem favorably against competitors in the Canadian market.
The timing of this launch, following the December 2023 U.S. release, demonstrates strong execution of Tandem's international expansion strategy. Being the first and only pump in Canada with this dual compatibility creates a competitive advantage. The free software update model for existing users helps maintain customer loyalty while potentially driving new adoption. Market leadership in automated insulin delivery systems, as evidenced by the #1 rating, suggests strong product acceptance and potential revenue growth in the Canadian market.
This regulatory milestone opens up significant market opportunities in Canada's diabetes care sector. The seamless upgrade path through remote software updates represents a scalable business model that could accelerate adoption rates while minimizing deployment costs. The partnership with Dexcom strengthens both companies' market positions and creates barriers to entry for competitors.
The planned January 2025 rollout for new customers with pre-loaded software indicates careful supply chain management and provides a clear timeline for revenue impact. The integration with Apple Watch adds a premium consumer tech angle that could attract younger demographics and tech-savvy users. Being first-to-market with G7 compatibility in Canada could help capture market share from competitors and potentially improve Tandem's international revenue mix.
t:slim X2 Insulin Pump with Dexcom G7 CGM (Photo: Business Wire)
“The commercial availability of this new offering is a testament to our decade-long partnership with Dexcom and shared commitment to continued leadership in advancing AID systems,” said Mark Novara, executive vice president and chief commercial officer of Tandem Diabetes Care. “Now, our t:slim X2 users in
“Through our continued partnership with Tandem, we have seen the proven benefits of automated insulin delivery. We’re proud that people living in
In December 2023, the t:slim X2 pump with Dexcom G7 integration launched in the
Tandem will email all in-warranty t:slim X2 users in
To check coverage and start the process of getting a Tandem insulin pump, please visit tandemdiabetes.ca.
To learn more about Dexcom G6 or Dexcom G7, please visit dexcom.com or ask your healthcare provider.
1 dQ&A Canada Patient Voice H1 2024.
2 Welsh JB, et al. J Diabetes Sci Technol. 2024;18(1):143-7
3 Dexcom G7 can complete warm up within 30 minutes, whereas other CGM brands require up to an hour or longer
4 Smart device sold separately. To view a list of compatible devices, visit dexcom.com/compatibility. Compatible smartphone is required to pair a new Dexcom G7 sensor with a compatible Apple Watch. Dexcom G7 users must continuously have their smartphone within 10 meters (33 feet) to utilize Share/Follow.
About Tandem Diabetes Care, Inc.
Tandem Diabetes Care, a global insulin delivery and diabetes technology company, manufactures and sells advanced automated insulin delivery systems that reduce the burden of diabetes management, while creating new possibilities for patients, their loved ones, and healthcare providers. The Company’s pump portfolio features the Tandem Mobi system and the t:slim X2 insulin pump, both of which feature Control-IQ advanced hybrid closed-loop technology. Tandem Diabetes Care is based in
Follow Tandem Diabetes Care on X @tandemdiabetes; use #tslimX2 and #TandemDiabetes.
Follow Tandem Diabetes Care on Facebook at facebook.com/TandemDiabetesCanada.
Follow Tandem Diabetes Care on LinkedIn at linkedin.com/company/tandemdiabetes.
© 2024 Tandem Diabetes Care, Inc. All rights reserved. Tandem Diabetes Care, the Tandem logo, Control-IQ, t:slim X2, and Tandem Mobi are either registered trademarks or trademarks of Tandem Diabetes Care, Inc. in
Forward-looking Statements
This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements relate to, among other things, the anticipated timing for the Canadian availability of the t:slim X2 pump with Dexcom G7 integration as well as our ability to provide the software update for current t:slim X2 pump users and the t:slim X2 pumps pre-loaded with Dexcom G7 integration software. These statements are subject to numerous risks and uncertainties, including our ability to start commercial scale manufacturing of the t:slim X2 pumps pre-loaded with Dexcom G7 integration software for the Canadian market, our ability to operate and maintain a system to facilitate online training for existing t:slim X2 pump customers upgrading their existing devices, and the risk that we may encounter other challenges that may delay the availability of t:slim X2 pumps pre-loaded with Dexcom G7 integration software. These and other risks are identified and described in greater detail under the “Risk Factors” heading of our most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and other documents filed with the Securities and Exchange Commission. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this release. Actual results could differ materially from those anticipated or projected in the forward-looking statements. Tandem undertakes no obligation to update or review any forward-looking statement in this press release because of new information, future events, or other factors.
Responsible Use of Control-IQ Technology
Control-IQ technology does not prevent all highs and lows. Users must still bolus for meals and actively manage their diabetes. Visit tandemdiabetes.com/safetyinfo for additional important safety information.
This product may not be right for you. Always read and follow the label.
Important Safety Information: The t:slim X2 insulin pump with Control-IQ technology (the System) consists of the t:slim X2 insulin pump, which contains Control-IQ technology, and a compatible continuous glucose monitor (CGM, sold separately). The t:slim X2 insulin pump is intended for the subcutaneous delivery of insulin, at set and variable rates, for the management of diabetes mellitus in people requiring insulin. The t:slim X2 insulin pump can be used solely for continuous insulin delivery and as part of the System. When used with a compatible CGM, the System can be used to automatically increase, decrease, and suspend delivery of basal insulin based on CGM sensor readings and predicted glucose values. The System can also deliver correction boluses when the glucose value is predicted to exceed a predefined threshold. The pump and the System are indicated for use in individuals 6 years of age and greater. The pump and the System are intended for single user use. The pump and the System are indicated for use with NovoRapid, Admelog, Trurapi, or Humalog U-100 insulin. The System is intended for the management of Type 1 diabetes.
WARNING: Control-IQ technology should not be used by anyone under the age of 6 years old. It should also not be used in users who require less than 10 units of insulin per day or who weigh less than 25 kilograms.
The System is not indicated for use in pregnant women, people on dialysis, or critically ill users. Do not use the System if using hydroxyurea.
Users of the pump and the System must: be willing and able to use the insulin pump, CGM, and all other system components in accordance with their respective instructions for use; test blood glucose levels as recommended by their healthcare provider; demonstrate adequate carb-counting skills; maintain sufficient diabetes self-care skills; see healthcare provider(s) regularly; and have adequate vision and/or hearing to recognize all functions of the pump, including alerts, alarms, and reminders. The t:slim X2 pump must be removed before MRI, CT, or diathermy treatment. Visit tandemdiabetes.com/safetyinfo for additional important safety information.
View source version on businesswire.com: https://www.businesswire.com/news/home/20241210731189/en/
Tandem Diabetes Care Media Contact:
858-366-6900
media@tandemdiabetes.com
Tandem Diabetes Care Investor Contact:
858-366-6900
IR@tandemdiabetes.com
Source: Tandem Diabetes Care, Inc.
FAQ
What recent authorization did Health Canada give related to TNDM?
When will Tandem start shipping t:slim X2 pumps with updated software in Canada?
What are the benefits of the Dexcom G7 CGM for t:slim X2 users in Canada?
How can in-warranty t:slim X2 users in Canada access the new compatibility feature?
What websites provide more information on the t:slim X2 insulin pump and Dexcom CGM systems?
